EVALUATION OF EFFECTIVENESS AND SAFETY OF RILPIVIRINE/EMTRICITABINE/TENOFOVIR

Andrés Rosado A[1], Ontañón Nasarre A[1], Carrasco Torrents A[1], Farfán Sedano FJ[1].
[1]Fuenlabrada University Hospital, Hospital Pharmacy, Madrid, Spain.
ana.andres@salud.madrid.org

BACKGROUND

The combination **rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF)** has been approved for the treatment of patients with HIV infection with a viral load (VL) ≤100.000 copies/mL.

PURPOSE

Evaluation of effectiveness and safety of RPV/TDF/FTC in naïve and pretreated patients with HIV infection in a second level hospital.

MATERIALS AND METHODS

- Retrospective observational study (June 2013-September 2014). Included patients with HIV infection, naïve and pretreated, on treatment with RPV/TDF/FTC.
- The effectiveness was measured through
  - **Virologic response** → VL was undetectable (**VL<50 copies/mL**) after 6 months of treatment.
  - **Immunological response** → **CD4 count was greater than 200 cells/mm^3** after 6 months of treatment.
- VL and CD4 count were collected at baseline and 6 months later. Patients who had less than 3 months on treatment were excluded, because no analytical data are available to assess the effectiveness.
- Security was evaluated through side effects (SE).

RESULTS

➢ 15 patients were included: 3 naïve and 12 pretreated. 42% (5/12) of pretreated switched treatment to RPV/TDF/FTC due to SE,25% (3/12) to simplify treatment, 25% (3/12) for psychiatrics reasons and 8% (1/12) for bad adherence.

BASELINE	UNDETECTABLE VL	VL 50-100 copies/mL	VL>100 copies/mL	CD4 count average (Cells/mm^3)
PRETREATED	67% (8/12)	8% (1/12)	25% (3/12)	377 (79-655)
NAÏVE	--	--	100% (3)	329 (200-430)





After 6 months, treatment were effective in a **75% (9/12) of pretreated and 67% (2/3) of naïve**.

➢ 13% (2/15) reported SE. 1 patient reported insomnia and another patient insomnia, fatigue, gastrointestinal disorders and dyspnea, due to left treatment.

CONCLUSION

- RPV/TDF/FTC has demonstrated to be effective in for treatment HIV infection, in naïve (67%) and in pretreated patients (75%).
- The SE profile is low, however one patient has left treatment due to this reason.

CP-163

20th Congress of EAHP.
Hamburg, Germany, 25-27 March 2015

The authors have no conflicts of interest to declare

eahp european association of hospital pharmacists

SaludMadrid

Hospital Universitario de Fuenlabrada

Comunidad de Madrid